Imipenem/cilastatin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

PneumoniaUrinary Tract InfectionVentilator-Associated Pneumonia

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

1

Imipenem/cilastatin

Merck & Co.

Approved

22

Primaxin

Pfizer

Preclinical

23

Acanya

Pfizer

Preclinical

14

Primaquine

Sanofi

Preclinical

15

Avlosulfon

AAlmirall, S.A.

Preclinical

46

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

127

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

28

Mycifradin

PPharmacia and Upjohn

Preclinical

19

Ofev

Boehringer Ingelheim

Preclinical

110

Pepcid

KKenvue Brands

Preclinical

1Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary Tract Infection4 trials

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

Completed·Shionogi·Phase 2·NCT02321800·452 enrolled

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

Completed·MMeiji Seika Pharma Co., Ltd.·Phase 3·NCT05887908·614 enrolled

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Completed·Pfizer·Phase 2·NCT00690378·137 enrolled

Show 1 more trial

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Completed·Merck & Co.·Phase 2·NCT01505634·302 enrolled

Intra-abdominal Infection2 trials

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

Completed·Pfizer·Phase 4·NCT01721408·470 enrolled

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

Completed·Merck & Co.·Phase 2·NCT01506271·351 enrolled

Pneumonia2 trials

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00515034·146 enrolled

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

Terminated·Pfizer·Phase 2·NCT00707239·108 enrolled

Intravenous1 trial

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Completed·EEntasis Therapeutics·Phase 1·NCT02971423·124 enrolled

Elderly1 trial

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Completed·EEvopoint Biosciences Inc.·Phase 1·NCT04801043·24 enrolled

3 more indications

Ventilator-Associated Pneumonia1 trial

Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

Unknown status·RRuijin Hospital·Phase 4·NCT01356472·60 enrolled

Bacterial Infection1 trial

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Completed·Merck & Co.·Phase 3·NCT02452047·50 enrolled

Acinetobacter Baumannii1 trial

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Completed·EEntasis Therapeutics·Phase 3·NCT03894046·207 enrolled

Details

Drug Info

Related News